Current targeting strategies for adenovirus vectors in cancer gene therapy

Current Cancer Drug Targets

Volumn 11, Issue 7, 2011, Pages 810-825

  Yao, X L ^a   Nakagawa, S ^b   Gao, J Q ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Adenovirus vector; Cancer therapy; Gene delivery; Gene therapy; Polyethylene glycol; Targeting; Targeting ligand; Tumor specific promoter

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ANTIBODY; CAPSID PROTEIN; COAT PROTEIN; FOLIC ACID; HYALURONIC ACID; LIGAND; MACROGOL; MUSCLE PROTEIN; PEPTIDE; POLYETHYLENEIMINE; POLYMER; TUMOR PROMOTER; VIRUS PROTEIN;

BACTERIAL GENE; CANCER GENE THERAPY; CLINICAL ASSESSMENT; CLINICAL FEATURE; DNA MODIFICATION; GENE EXPRESSION; GENE MUTATION; GENE TECHNOLOGY; GENETIC ENGINEERING AND GENE TECHNOLOGY; GENETIC TRANSFECTION; HUMAN; INTROSPECTION; NEOPLASM; NONHUMAN; PROMOTER REGION; REVIEW; TRANSGENE; TROPISM; VIRUS UNCOATING;

ADENOVIRIDAE; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 80051697994     PISSN: 15680096     EISSN: 18735576     Source Type: Journal    
DOI: 10.2174/156800911796798896     Document Type: Review

References (154)

1. World Health Organization. Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/index.html (Accessed by Jun 28, 2011)
2. Anderson, W. F.; Blaese, R. M.; Culver, K. The ADA human gene therapy clinical protocol: Points to Consider response with clinical protocol, July 6, 1990. Hum Gene Ther. 1990, 1, 331-62.
3. WILEY. Gene Therapy Clinical Trials Worldwide. http://www.wiley.com/legacy/wileychi/genmed/clinical/ (Accessed by Jun 28, 2011)
4. Mizuguchi, H.; Hayakawa, T. Targeted adenovirus vectors. Hum Gene Ther. 2004, 15, 1034-44.
5. Eto, Y.; Yoshioka, Y.; Mukai, Y.; Okada, N.; Nakagawa, S. Development of PEGylated adenovirus vector with targeting ligand. Int. J. Pharm. 2008, 354, 3-8.
6. Sterman, D. H.; Recio, A.; Haas, A. R.; Vachani, A.; Katz, S. I.; Gillespie, C. T.; Cheng, G.; Sun, J.; Moon, E.; Pereira, L.; Wang, X.; Heitjan, D. F.; Litzky, L.; June, C. H.; Vonderheide, R. H.; Carroll, R. G.; Albelda, S. M. A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions. Mol. Ther. 2010, 18, 852-860.
7. Li, Y.; Li, L. J.; Zhang, S. T.; Wang, L. J.; Zhang, Z.; Gao, N.; Zhang, Y. Y.; Chen, Q. M. In vitro and clinical studies of gene therapy with recombinant human adenovirus-p53 injection for oral leukoplakia. Clin. Cancer Res. 2009, 15, 6724-6731.
8. Korn, W. M.; Macal, M.; Christian, C.; Lacher, M. D.; McMillan, A.; Rauen, K. A.; Warren, R. S.; Ferrell, L. Expression of the coxsackievirus- and adenovirus receptor in gastrointestinal cancer correlates with tumor differentiation. Cancer Gene Ther. 2006, 13, 792-797.
9. Yao, X.; Yoshioka, Y.; Eto, Y.; Morishige, T.; Okada, Y.; Mizuguchi, H.; Mukai, Y.; Okada, N.; Nakagawa, S. TERT promoter-driven adenovirus vector for cancer gene therapy via systemic injection. Biochem. Biophys. Res. Commun. 2007, 362, 419-424.
10. Okada, N.; Iiyama, S.; Okada, Y.; Mizuguchi, H.; Hayakawa, T.; Nakagawa, S.; Mayumi, T.; Fujita, T.; Yamamoto, A. Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12. Cancer Gene Ther. 2005, 12, 72-83.
11. Zheng, C.; Nikolov, N. P.; Alevizos, I.; Cotrim, A. P.; Liu, S.; McCullagh, L.; Chiorini, J. A.; Illei, G. G.; Baum, B. J. Transient detection of E1-containing adenovirus in saliva after the delivery of a first-generation adenoviral vector to human parotid gland. J. Gene Med. 2010, 12, 3-10.
12. Lehrman, S. Virus treatment questioned after gene therapy death. Nature 1999, 401, 517-518.
13. Rux, J. J.; Burnett, R. M. Adenovirus structure. Hum. Gene Ther. 2004, 15, 1167-1176.
14. Xia, D.; Henry, L. J.; Gerard, R. D.; Deisenhofer, J. Crystal structure of the receptor-binding domain of adenovirus type 5 fiber protein at 1.7 A resolution. Structure 1994, 2, 1259-1270.
15. Meier, O.; Boucke, K.; Hammer, S. V.; Keller, S.; Stidwill, R. P.; Hemmi, S.; Greber, U. F. Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake. J. Cell Biol. 2002, 158, 1119-1131.
16. Wickham, T. J.; Mathias, P.; Cheresh, D. A.; Nemerow, G. R. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell 1993, 73, 309-319.
17. Meier, O.; Greber, U. F. Adenovirus endocytosis. J. Gene Med. 2004, 6 Suppl 1, S152-S163.
18. Bett, A. J.; Haddara, W.; Prevec, L.; Graham, F. L. An efficient and flexible system for construction of adenovirus vectors with insertions or deletions in early regions 1 and 3. Proc. Natl. Acad. Sci. U S A 1994, 91, 8802-8806.
19. Bett, A. J.; Prevec, L.; Graham, F. L. Packaging capacity and stability of human adenovirus type 5 vectors. J. Virol. 1993, 67, 5911-5921.
20. van de Ven, R.; Lindenberg, J. J.; Oosterhoff, D.; van den Tol, M. P.; Rosalia, R. A.; Murakami, M.; Everts, M.; Scheffer, G. L.; Scheper, R. J.; de Gruijl, T. D.; Curiel, D. T. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J. Immunother. 2009, 32, 895-906.
21. Yoshioka, Y.; Asavatanabodee, R.; Eto, Y.; Watanabe, H.; Morishige, T.; Yao, X.; Kida, S.; Maeda, M.; Mukai, Y.; Mizuguchi, H.; Kawasaki, K.; Okada, N.; Nakagawa, S. Tat conjugation of adenovirus vector broadens tropism and enhances transduction efficiency. Life Sci. 2008, 83, 747-755.
22. Murakami, S.; Sakurai, F.; Kawabata, K.; Okada, N.; Fujita, T.; Yamamoto, A.; Hayakawa, T.; Mizuguchi, H. Interaction of penton base Arg-Gly-Asp motifs with integrins is crucial for adenovirus serotype 35 vector transduction in human hematopoietic cells. Gene Ther. 2007, 14, 1525-1533.
23. Michael, S. I.; Hong, J. S.; Curiel, D. T.; Engler, J. A. Addition of a short peptide ligand to the adenovirus fiber protein. Gene Ther. 1995, 2, 660-668.
24. Wickham, T. J.; Tzeng, E.; Shears, L. L., 2nd; Roelvink, P. W.; Li, Y.; Lee, G. M.; Brough, D. E.; Lizonova, A.; Kovesdi, I. Increased in vitro and in vivo gene transfer by adenovirus vectors containing chimeric fiber proteins. J. Virol. 1997, 71, 8221-8229.
25. Barnett, B. G.; Crews, C. J.; Douglas, J. T. Targeted adenoviral vectors. Biochim. Biophys. Acta. 2002, 1575, 1-14.
26. Mizuguchi, H.; Koizumi, N.; Hosono, T.; Utoguchi, N.; Watanabe, Y.; Kay, M. A.; Hayakawa, T. A simplified system for constructing recombinant adenoviral vectors containing heterologous peptides in the HI loop of their fiber knob. Gene Ther. 2001, 8, 730-735.
27. Krasnykh, V.; Dmitriev, I.; Mikheeva, G.; Miller, C. R.; Belousova, N.; Curiel, D. T. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J. Virol. 1998, 72, 1844-1852.
28. Krasnykh, V.; Dmitriev, I.; Navarro, J. G.; Belousova, N.; Kashentseva, E.; Xiang, J.; Douglas, J. T.; Curiel, D. T. Advanced generation adenoviral vectors possess augmented gene transfer efficiency based upon coxsackie adenovirus receptor-independent cellular entry capacity. Cancer Res. 2000, 60, 6784-6787.
29. Dmitriev, I.; Krasnykh, V.; Miller, C. R.; Wang, M.; Kashentseva, E.; Mikheeva, G.; Belousova, N.; Curiel, D. T. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptorindependent cell entry mechanism. J. Virol. 1998, 72, 9706-9713.
30. Hidaka, C.; Milano, E.; Leopold, P. L.; Bergelson, J. M.; Hackett, N. R.; Finberg, R. W.; Wickham, T. J.; Kovesdi, I.; Roelvink, P.; Crystal, R. G. CAR-dependent and CAR-independent pathways of adenovirus vector-mediated gene transfer and expression in human fibroblasts. J. Clin. Invest. 1999, 103, 579-587.
31. Belousova, N.; Krendelchtchikova, V.; Curiel, D. T.; Krasnykh, V. Modulation of adenovirus vector tropism via incorporation of polypeptide ligands into the fiber protein. J. Virol. 2002, 76, 8621-8631.
32. Kanerva, A.; Wang, M.; Bauerschmitz, G. J.; Lam, J. T.; Desmond, R. A.; Bhoola, S. M.; Barnes, M. N.; Alvarez, R. D.; Siegal, G. P.; Curiel, D. T.; Hemminki, A. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol. Ther. 2002, 5, 695-704.
33. Kasono, K.; Blackwell, J. L.; Douglas, J. T.; Dmitriev, I.; Strong, T. V.; Reynolds, P.; Kropf, D. A.; Carroll, W. R.; Peters, G. E.; Bucy, R. P.; Curiel, D. T.; Krasnykh, V. Selective gene delivery tohead and neck cancer cells via an integrin targeted adenoviral vector. Clin. Cancer Res. 1999, 5, 2571-2579.
34. Garcia-Castro, J.; Segovia, J. C.; Garcia-Sanchez, F.; Lillo, R.; Gomez-Navarro, J.; Curiel, D. T.; Bueren, J. A. Selective transduction of murine myelomonocytic leukemia cells (WEHI-3B) with regular and RGD-adenoviral vectors. Mol. Ther. 2001, 3, 70-77.
35. Okada, N.; Tsukada, Y.; Nakagawa, S.; Mizuguchi, H.; Mori, K.; Saito, T.; Fujita, T.; Yamamoto, A.; Hayakawa, T.; Mayumi, T. Efficient gene delivery into dendritic cells by fiber-mutant adenovirus vectors. Biochem. Biophys. Res. Commun. 2001, 282, 173-179.
36. Koizumi, N.; Mizuguchi, H.; Utoguchi, N.; Watanabe, Y.; Hayakawa, T. Generation of fiber-modified adenovirus vectors containing heterologous peptides in both the HI loop and C terminus of the fiber knob. J. Gene Med. 2003, 5, 267-276.
37. Kurachi, S.; Tashiro, K.; Sakurai, F.; Sakurai, H.; Kawabata, K.; Yayama, K.; Okamoto, H.; Nakagawa, S.; Mizuguchi, H. Fibermodified adenovirus vectors containing the TAT peptide derived from HIV-1 in the fiber knob have efficient gene transfer activity. Gene Ther. 2007, 14, 1160-1165.
38. Mizuguchi, H.; Hayakawa, T. Enhanced antitumor effect and reduced vector dissemination with fiber-modified adenovirus vectors expressing herpes simplex virus thymidine kinase. Cancer Gene Ther. 2002, 9, 236-242.
39. Gao, J. Q.; Tsuda, Y.; Katayama, K.; Nakayama, T.; Hatanaka, Y.; Tani, Y.; Mizuguchi, H.; Hayakawa, T.; Yoshie, O.; Tsutsumi, Y.; Mayumi, T.; Nakagawa, S. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumorcells through a recombinant adenovirus vector. Cancer Res. 2003, 63, 4420-4425.
40. Okada, N.; Saito, T.; Masunaga, Y.; Tsukada, Y.; Nakagawa, S.; Mizuguchi, H.; Mori, K.; Okada, Y.; Fujita, T.; Hayakawa, T.; Mayumi, T.; Yamamoto, A. Efficient antigen gene transduction using Arg-Gly-Asp fiber-mutant adenovirus vectors can potentiate antitumor vaccine efficacy and maturation of murine dendritic cells. Cancer Res. 2001, 61, 7913-7919.
41. Okada, N.; Masunaga, Y.; Okada, Y.; Mizuguchi, H.; Iiyama, S.; Mori, N.; Sasaki, A.; Nakagawa, S.; Mayumi, T.; Hayakawa, T.; Fujita, T.; Yamamoto, A. Dendritic cells transduced with gp100 gene by RGD fiber-mutant adenovirus vectors are highly efficacious in generating anti-B16BL6 melanoma immunity in mice. Gene Ther. 2003, 10, 1891-1902.
42. Okada, N.; Mori, N.; Koretomo, R.; Okada, Y.; Nakayama, T.; Yoshie, O.; Mizuguchi, H.; Hayakawa, T.; Nakagawa, S.; Mayumi, T.; Fujita, T.; Yamamoto, A. Augmentation of the migratory ability of DC-based vaccine into regional lymph nodes by efficient CCR7 gene transduction. Gene Ther. 2005, 12, 129-139.
43. Bewley, M. C.; Springer, K.; Zhang, Y. B.; Freimuth, P.; Flanagan, J. M. Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR. Science 1999, 286, 1579-1583.
44. Kirby, I.; Davison, E.; Beavil, A. J.; Soh, C. P.; Wickham, T. J.; Roelvink, P. W.; Kovesdi, I.; Sutton, B. J.; Santis, G. Mutations in the DG loop of adenovirus type 5 fiber knob protein abolish highaffinity binding to its cellular receptor CAR. J. Virol. 1999, 73, 9508-9514.
45. Nakamura, T.; Sato, K.; Hamada, H. Reduction of natural adenovirus tropism to the liver by both ablation of fibercoxsackievirus and adenovirus receptor interaction and use of replaceable short fiber. J. Virol. 2003, 77, 2512-2521.
46. Koizumi, N.; Mizuguchi, H.; Sakurai, F.; Yamaguchi, T.; Watanabe, Y.; Hayakawa, T. Reduction of natural adenovirus tropism to mouse liver by fiber-shaft exchange in combination with both CAR- and alphav integrin-binding ablation. J. Virol. 2003, 77, 13062-13072.
47. Koizumi, N.; Kawabata, K.; Sakurai, F.; Watanabe, Y.; Hayakawa, T.; Mizuguchi, H. Modified adenoviral vectors ablated for coxsackievirus-adenovirus receptor, alphav integrin, and heparin sulfate binding reduce in vivo tissue transduction and toxicity. Hum. Gene Ther. 2006, 17, 264-279.
48. Nicklin, S. A.; White, S. J.; Watkins, S. J.; Hawkins, R. E.; Baker, A. H. Selective targeting of gene transfer to vascular endothelial cells by use of peptides isolated by phage display. Circulation 2000, 102, 231-237.
49. Lee, T. Y.; Lin, C. T.; Kuo, S. Y.; Chang, D. K.; Wu, H. C. Peptide-mediated targeting to tumor blood vessels of lung cancer for drug delivery. Cancer Res. 2007, 67, 10958-10965.
50. Nicklin, S. A.; Von Seggern, D. J.; Work, L. M.; Pek, D. C.; Dominiczak, A. F.; Nemerow, G. R.; Baker, A. H. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol. Ther. 2001, 4, 534-542.
51. Pereboev, A.; Pereboeva, L.; Curiel, D. T. Phage display of adenovirus type 5 fiber knob as a tool for specific ligand selection and validation. J. Virol. 2001, 75, 7107-7113.
52. Xia, H.; Anderson, B.; Mao, Q.; Davidson, B. L. Recombinant human adenovirus: targeting to the human transferrin receptor improves gene transfer to brain microcapillary endothelium. J. Virol. 2000, 74, 11359-11366.
53. Denby, L.; Work, L. M.; Graham, D.; Hsu, C.; von Seggern, D. J.; Nicklin, S. A.; Baker, A. H. Adenoviral serotype 5 vectors pseudotyped with fibers from subgroup D show modified tropism in vitro and in vivo. Hum. Gene Ther. 2004, 15, 1054-1064.
54. Rea, D.; Havenga, M. J.; van Den Assem, M.; Sutmuller, R. P.; Lemckert, A.; Hoeben, R. C.; Bout, A.; Melief, C. J.; Offringa, R. Highly efficient transduction of human monocyte-derived dendritic cells with subgroup B fiber-modified adenovirus vectors enhances transgene-encoded antigen presentation to cytotoxic T cells. J. Immunol. 2001, 166, 5236-5244.
55. Takayama, K.; Reynolds, P. N.; Short, J. J.; Kawakami, Y.; Adachi, Y.; Glasgow, J. N.; Rots, M. G.; Krasnykh, V.; Douglas, J. T.; Curiel, D. T. A mosaic adenovirus possessing serotype Ad5 and serotype Ad3 knobs exhibits expanded tropism. Virology 2003, 309, 282-293.
56. Gall, J.; Kass-Eisler, A.; Leinwand, L.; Falck-Pedersen, E. Adenovirus type 5 and 7 capsid chimera: fiber replacement alters receptor tropism without affecting primary immune neutralization epitopes. J. Virol. 1996, 70, 2116-2123.
57. Mizuguchi, H.; Hayakawa, T. Adenovirus vectors containing chimeric type 5 and type 35 fiber proteins exhibit altered and expanded tropism and increase the size limit of foreign genes. Gene 2002, 285, 69-77.
58. Sakurai, F.; Mizuguchi, H.; Yamaguchi, T.; Hayakawa, T. Characterization of in vitro and in vivo gene transfer properties of adenovirus serotype 35 vector. Mol. Ther. 2003, 8, 813-821.
59. Vigne, E.; Mahfouz, I.; Dedieu, J. F.; Brie, A.; Perricaudet, M.; Yeh, P. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J. Virol. 1999, 73, 5156-5161.
60. Wickham, T. J.; Carrion, M. E.; Kovesdi, I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther. 1995, 2, 750-756.
61. Rosa-Calatrava, M.; Grave, L.; Puvion-Dutilleul, F.; Chatton, B.; Kedinger, C. Functional analysis of adenovirus protein IX identifies domains involved in capsid stability, transcriptional activity, and nuclear reorganization. J. Virol. 2001, 75, 7131-7141.
62. Douglas, J. T.; Miller, C. R.; Kim, M.; Dmitriev, I.; Mikheeva, G.; Krasnykh, V.; Curiel, D. T. A system for the propagation of adenoviral vectors with genetically modified receptor specificities. Nat. Biotechnol. 1999, 17, 470-475.
63. Dmitriev, I. P.; Kashentseva, E. A.; Curiel, D. T. Engineering of adenovirus vectors containing heterologous peptide sequences in the C terminus of capsid protein IX. J. Virol. 2002, 76, 6893-6899.
64. Kurachi, S.; Koizumi, N.; Sakurai, F.; Kawabata, K.; Sakurai, H.; Nakagawa, S.; Hayakawa, T.; Mizuguchi, H. Characterization of capsid-modified adenovirus vectors containing heterologous peptides in the fiber knob, protein IX, or hexon. Gene Ther. 2006.
65. Mizuguchi, H.; Hayakawa, T. Characteristics of adenovirusmediated tetracycline-controllable expression system. Biochim. Biophys. Acta. 2001, 1568, 21-29.
66. Mizuguchi, H.; Hayakawa, T. The tet-off system is more effective than the tet-on system for regulating transgene expression in a single adenovirus vector. J. Gene Med. 2002, 4, 240-247.
67. Mizuguchi, H.; Xu, Z. L.; Sakurai, F.; Mayumi, T.; Hayakawa, T. Tight positive regulation of transgene expression by a single adenovirus vector containing the rtTA and tTS expression cassettes in separate genome regions. Hum. Gene Ther. 2003, 14, 1265-1277.
68. Mizuguchi, H.; Xu, Z. L.; Sakurai, F.; Kawabata, K.; Yamaguchi, T.; Hayakawa, T. Efficient regulation of gene expression using self-contained fiber-modified adenovirus vectors containing the tetoff system. J. Control Release 2005, 110, 202-211.
69. Gupta, S.; Schoer, R. A.; Egan, J. E.; Hannon, G. J.; Mittal, V. Inducible, reversible, and stable RNA interference in mammalian cells. Proc. Natl. Acad. Sci. U S A 2004, 101, 1927-32.
70. Kunath, T.; Gish, G.; Lickert, H.; Jones, N.; Pawson, T.; Rossant, J. Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. Nat. Biotechnol. 2003, 21, 559-561.
71. Sumimoto, H.; Yamagata, S.; Shimizu, A.; Miyoshi, H.; Mizuguchi, H.; Hayakawa, T.; Miyagishi, M.; Taira, K.; Kawakami, Y. Gene therapy for human small-cell lung carcinoma by inactivation of Skp-2 with virally mediated RNA interference. Gene Ther. 2005, 12, 95-100.
72. Haviv, Y. S.; van Houdt, W. J.; Lu, B.; Curiel, D. T.; Zhu, Z. B. Transcriptional targeting in renal cancer cell lines via the human CXCR4 promoter. Mol. Cancer Ther. 2004, 3, 687-691.
73. Jeong, J. S.; Lee, S. W.; Hong, S. H.; Lee, Y. J.; Jung, H. I.; Cho, K. S.; Seo, H. H.; Lee, S. J.; Park, S.; Song, M. S.; Kim, C. M.; Kim, I. H. Antitumor effects of systemically delivered adenovirus harboring trans-splicing ribozyme in intrahepatic colon cancer mouse model. Clin. Cancer Res. 2008, 14, 281-290.
74. Robson, T.; Hirst, D. G. Transcriptional targeting in cancer gene therapy. J. Biomed. Biotechnol. 2003, 2003, 110-137.
75. Osaki, T.; Tanio, Y.; Tachibana, I.; Hosoe, S.; Kumagai, T.; Kawase, I.; Oikawa, S.; Kishimoto, T. Gene therapy for carcinoembryonic antigen-producing human lung cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 1994, 54, 5258-5261.
76. Nicklin, S. A.; Reynolds, P. N.; Brosnan, M. J.; White, S. J.; Curiel, D. T.; Dominiczak, A. F.; Baker, A. H. Analysis of cellspecific promoters for viral gene therapy targeted at the vascular endothelium. Hypertension 2001, 38, 65-70.
77. Morishita, K.; Johnson, D. E.; Williams, L. T. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J. Biol. Chem. 1995, 270, 27948-27953.
78. Oshikiri, T.; Miyamoto, M.; Hiraoka, K.; Shichinohe, T.; Kawarada, Y.; Kato, K.; Suzuoki, M.; Nakakubo, Y.; Kondo, S.; Dosaka-Akita, H.; Kasahara, N.; Katoh, H. Transcriptional targeting of adenovirus vectors with the squamous cell carcinomaspecific antigen-2 promoter for selective apoptosis induction in lung cancer. Cancer Gene Ther. 2006, 13, 856-863.
79. Qiu, C.; De Young, M. B.; Finn, A.; Dichek, D. A. Cationic liposomes enhance adenovirus entry via a pathway independent of the fiber receptor and alpha(v)-integrins. Hum. Gene Ther. 1998, 9, 507-520.
80. Lee, E. M.; Hong, S. H.; Lee, Y. J.; Kang, Y. H.; Choi, K. C.; Choi, S. H.; Kim, I. H.; Lim, S. J. Liposome-complexed adenoviral gene transfer in cancer cells expressing various levels of coxsackievirus and adenovirus receptor. J. Cancer Res. Clin. Oncol. 2004, 130, 169-177.
81. Clark, P. R.; Stopeck, A. T.; Brailey, J. L.; Wang, Q.; McArthur, J.; Finer, M. H.; Hersh, E. M. Polycations and cationic lipids enhance adenovirus transduction and transgene expression in tumor cells. Cancer Gene Ther. 1999, 6, 437-446.
82. Yotnda, P.; Chen, D. H.; Chiu, W.; Piedra, P. A.; Davis, A.; Templeton, N. S.; Brenner, M. K. Bilamellar cationic liposomes protect adenovectors from preexisting humoral immune responses. Mol. Ther. 2002, 5, 233-241.
83. Steel, J. C.; Cavanagh, H. M.; Burton, M. A.; Dingwall, D. J.; Kalle, W. H. Modification of liposomal concentration in liposome/adenoviral complexes allows significant protection of adenoviral vectors from neutralising antibody, in vitro. J. Virol. Methods 2005, 126, 31-36.
84. Ma, Z.; Mi, Z.; Wilson, A.; Alber, S.; Robbins, P. D.; Watkins, S.; Pitt, B.; Li, S. Redirecting adenovirus to pulmonary endothelium by cationic liposomes. Gene Ther. 2002, 9, 176-182.
85. Dodds, E.; Piper, T. A.; Murphy, S. J.; Dickson, G. Cationic lipids and polymers are able to enhance adenoviral infection of cultured mouse myotubes. J. Neurochem. 1999, 72, 2105-2112.
86. Croyle, M. A.; Cheng, X.; Sandhu, A.; Wilson, J. M. Development of novel formulations that enhance adenoviral-mediated gene expression in the lung in vitro and in vivo. Mol. Ther. 2001, 4, 22-28.
87. Kawamata, Y.; Nagayama, Y.; Nakao, K.; Mizuguchi, H.; Hayakawa, T.; Sato, T.; Ishii, N. Receptor-independent augmentation of adenovirus-mediated gene transfer with chitosan in vitro. Biomaterials 2002, 23, 4573-4579.
88. Park, J. W.; Mok, H.; Park, T. G. Physical adsorption of PEG grafted and blocked poly-L-lysine copolymers on adenovirus surface for enhanced gene transduction. J. Control Release 2010, 142, 238-244.
89. Singh, R.; Al-Jamal, K. T.; Lacerda, L.; Kostarelos, K. Nanoengineering artificial lipid envelopes around adenovirus by self-assembly. ACS Nano. 2008, 2, 1040-1050.
90. Singh, R.; Tian, B.; Kostarelos, K. Artificial envelopment of nonenveloped viruses: enhancing adenovirus tumor targeting in vivo. FASEB J. 2008, 22, 3389-3402.
91. Han, J.; Zhao, D.; Zhong, Z.; Zhang, Z.; Gong, T.; Sun, X. Combination of adenovirus and cross-linked low molecular weight PEI improves efficiency of gene transduction. Nanotechnology 2010, 21, 105106.
92. Yoshihara, C.; Hamada, K.; Koyama, Y. Preparation of a novel adenovirus formulation with artificial envelope of multilayer polymer-coatings: therapeutic effect on metastatic ovarian cancer. Oncol. Rep. 2010, 23, 733-738.
93. Park, Y.; Kang, E.; Kwon, O. J.; Hwang, T.; Park, H.; Lee, J. M.; Kim, J. H.; Yun, C. O. Ionically crosslinked Ad/chitosan nanocomplexes processed by electrospinning for targeted cancer gene therapy. J. Control Release 2010, 148, 75-82.
94. Kim, P. H.; Kim, T. I.; Yockman, J. W.; Kim, S. W.; Yun, C. O. The effect of surface modification of adenovirus with an argininegrafted bioreducible polymer on transduction efficiency and immunogenicity in cancer gene therapy. Biomaterials 2010, 31, 1865-1874.
95. Konak, C.; Subr, V.; Kostka, L.; Stepanek, P.; Ulbrich, K.; Schlaad, H. Coating of vesicles with hydrophilic reactive polymers. Langmuir. 2008, 24, 7092-7098.
96. Wang, D.; Molavi, O.; Lutsiak, M. E.; Elamanchili, P.; Kwon, G. S.; Samuel, J. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination. J. Pharm. Pharm. Sci. 2007, 10, 217-230.
97. Hatefi, A.; Cappello, J.; Ghandehari, H. Adenoviral gene delivery to solid tumors by recombinant silk-elastinlike protein polymers. Pharm. Res. 2007, 24, 773-779.
98. Cresce, A. W.; Dandu, R.; Burger, A.; Cappello, J.; Ghandehari, H. Characterization and real-time imaging of gene expression of adenovirus embedded silk-elastinlike protein polymer hydrogels. Mol. Pharm. 2008, 5, 891-897.
99. Gustafson, J.; Greish, K.; Frandsen, J.; Cappello, J.; Ghandehari, H. Silk-elastinlike recombinant polymers for gene therapy of head and neck cancer: from molecular definition to controlled gene expression. J. Control Release 2009, 140, 256-261.
100. Greish, K.; Araki, K.; Li, D.; O'Malley, B. W., Jr.; Dandu, R.; Frandsen, J.; Cappello, J.; Ghandehari, H. Silk-elastinlike protein polymer hydrogels for localized adenoviral gene therapy of head and neck tumors. Biomacromolecules 2009, 10, 2183-2188.
101. Gustafson, J. A.; Price, R. A.; Greish, K.; Cappello, J.; Ghandehari, H. Silk-elastin-like hydrogel improves the safety of adenovirusmediated gene-directed enzyme-prodrug therapy. Mol. Pharm. 2010, 7, 1050-1056.
102. Dmitriev, I.; Kashentseva, E.; Rogers, B. E.; Krasnykh, V.; Curiel, D. T. Ectodomain of coxsackievirus and adenovirus receptor genetically fused to epidermal growth factor mediates adenovirus targeting to epidermal growth factor receptor-positive cells. J. Virol. 2000, 74, 6875-6884.
103. Douglas, J. T.; Rogers, B. E.; Rosenfeld, M. E.; Michael, S. I.; Feng, M.; Curiel, D. T. Targeted gene delivery by tropismmodified adenoviral vectors. Nat. Biotechnol. 1996, 14, 1574-1578.
104. Gu, D. L.; Gonzalez, A. M.; Printz, M. A.; Doukas, J.; Ying, W.; D'Andrea, M.; Hoganson, D. K.; Curiel, D. T.; Douglas, J. T.; Sosnowski, B. A.; Baird, A.; Aukerman, S. L.; Pierce, G. F. Fibroblast growth factor 2 retargeted adenovirus has redirected cellular tropism: evidence for reduced toxicity and enhanced antitumor activity in mice. Cancer Res. 1999, 59, 2608-2614.
105. Wang, W.; Zhu, N. L.; Chua, J.; Swenson, S.; Costa, F. K.; Schmitmeier, S.; Sosnowski, B. A.; Shichinohe, T.; Kasahara, N.; Chen, T. C. Retargeting of adenoviral vector using basic fibroblast growth factor ligand for malignant glioma gene therapy. J. Neurosurg. 2005, 103, 1058-1066.
106. Henning, P.; Magnusson, M. K.; Gunneriusson, E.; Hong, S. S.; Boulanger, P.; Nygren, P. A.; Lindholm, L. Genetic modification of adenovirus 5 tropism by a novel class of ligands based on a threehelix bundle scaffold derived from staphylococcal protein A. Hum. Gene Ther. 2002, 13, 1427-1439.
107. Horowitz, J. Adenovirus-mediated p53 gene therapy: overview of preclinical studies and potential clinical applications. Curr. Opin. Mol. Ther. 1999, 1, 500-509.
108. Vattemi, E.; Claudio, P. P. Adenoviral gene therapy in head and neck cancer. Drug News Perspect. 2006, 19, 329-337.
109. Gabrilovich, D. I. INGN 201 (Advexin): adenoviral p53 gene therapy for cancer. Expert Opinion on Biological Therapy 2006, 6, 823-832.
110. Kim, S.; Peng, Z.; Kaneda, Y. Current status of gene therapy in Asia. Mol. Ther. 2008, 16, 237-243.
111. Alemany, R.; Suzuki, K.; Curiel, D. T. Blood clearance rates of adenovirus type 5 in mice. J. Gen. Virol. 2000, 81, 2605-2609.
112. Koizumi, N.; Yamaguchi, T.; Kawabata, K.; Sakurai, F.; Sasaki, T.; Watanabe, Y.; Hayakawa, T.; Mizuguchi, H. Fiber-modified adenovirus vectors decrease liver toxicity through reduced IL-6 production. J. Immunol. 2007, 178, 1767-1773.
113. Fisher, K. D.; Seymour, L. W. HPMA copolymers for masking and retargeting of therapeutic viruses. Adv. Drug Deliv. Rev. 2010, 62, 240-245.
114. Fisher, K. D.; Stallwood, Y.; Green, N. K.; Ulbrich, K.; Mautner, V.; Seymour, L. W. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther. 2001, 8, 341-348.
115. Carlisle, R. C.; Di, Y.; Cerny, A. M.; Sonnen, A. F.; Sim, R. B.; Green, N. K.; Subr, V.; Ulbrich, K.; Gilbert, R. J.; Fisher, K. D.; Finberg, R. W.; Seymour, L. W. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virusadenovirus receptor and complement receptor 1. Blood 2009, 113, 1909-1918.
116. Green, N. K.; Herbert, C. W.; Hale, S. J.; Hale, A. B.; Mautner, V.; Harkins, R.; Hermiston, T.; Ulbrich, K.; Fisher, K. D.; Seymour, L. W. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther. 2004, 11, 1256-1263.
117. Morrison, J.; Briggs, S. S.; Green, N.; Fisher, K.; Subr, V.; Ulbrich, K.; Kehoe, S.; Seymour, L. W. Virotherapy of ovarian cancer with polymer-cloaked adenovirus retargeted to the epidermal growth factor receptor. Mol. Ther. 2008, 16, 244-251.
118. Wang, I. J.; Jhuang, M. C.; Chen, Y. H.; Yeh, L. K.; Liu, C. Y.; Young, T. H. Chitosan modification of adenovirus to modify transfection efficiency in bovine corneal epithelial cells. PLoS One. 2010, 5, e12085.
119. Hu, W. W.; Elkasabi, Y.; Chen, H. Y.; Zhang, Y.; Lahann, J.; Hollister, S. J.; Krebsbach, P. H. The use of reactive polymer coatings to facilitate gene delivery from poly (epsiloncaprolactone) scaffolds. Biomaterials 2009, 30, 5785-5792.
120. Elkasabi, Y. M.; Lahann, J.; Krebsbach, P. H. Cellular transduction gradients via vapor-deposited polymer coatings. Biomaterials 2011, 32, 1809-1815.
121. Delgado, C.; Francis, G. E.; Fisher, D. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. 1992, 9, 249-304.
122. Harris, J. M.; Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2, 214-221.
123. Asselin, B. L. The three asparaginases. Comparative pharmacology and optimal use in childhood leukemia. Adv. Exp. Med. Biol. 1999, 457, 621-629.
124. Hershfield, M. S. PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 years. Clin Immunol Immunopathol. 1995, 76, S228-232.
125. Nieforth, K. A.; Nadeau, R.; Patel, I. H.; Mould, D. Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin. Pharmacol. Ther. 1996, 59, 636-646.
126. Montaguti, P.; Melloni, E.; Cavalletti, E. Acute intravenous toxicity of dimethyl sulfoxide, polyethylene glycol 400, dimethylformamide, absolute ethanol, and benzyl alcohol in inbred mouse strains. Arzneimittelforschung. 1994, 44, 566-570.
127. O'Riordan, C. R.; Lachapelle, A.; Delgado, C.; Parkes, V.; Wadsworth, S. C.; Smith, A. E.; Francis, G. E. PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum. Gene Ther. 1999, 10, 1349-1358.
128. Croyle, M. A.; Yu, Q. C.; Wilson, J. M. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Hum.Gene Ther. 2000, 11, 1713-1722.
129. Croyle, M. A.; Chirmule, N.; Zhang, Y.; Wilson, J. M. "Stealth" adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J. Virol. 2001, 75, 4792-4801.
130. Gao, J. Q.; Eto, Y.; Yoshioka, Y.; Sekiguchi, F.; Kurachi, S.; Morishige, T.; Yao, X.; Watanabe, H.; Asavatanabodee, R.; Sakurai, F.; Mizuguchi, H.; Okada, Y.; Mukai, Y.; Tsutsumi, Y.; Mayumi, T.; Okada, N.; Nakagawa, S. Effective tumor targeted gene transfer using PEGylated adenovirus vector via systemic administration. J. Control Release 2007, 122, 102-110.
131. Yao, X.; Yoshioka, Y.; Morishige, T.; Eto, Y.; Watanabe, H.; Okada, Y.; Mizuguchi, H.; Mukai, Y.; Okada, N.; Nakagawa, S. Systemic administration of a PEGylated adenovirus vector with a cancer-specific promoter is effective in a mouse model of metastasis. Gene Ther. 2009, 16, 1395-1404.
132. Yao, X.; Yoshioka, Y.; Morishige, T.; Eto, Y.; Narimatsu, S.; Mizuguchi, H.; Mukai, Y.; Okada, N.; Nakagawa, S. Adenovirus vector covalently conjugated to polyethylene glycol with a cancerspecific promoter suppresses the tumor growth through systemic administration. Biol. Pharm. Bull. 2010, 33, 1073-1076.
133. Wortmann, A.; Vohringer, S.; Engler, T.; Corjon, S.; Schirmbeck, R.; Reimann, J.; Kochanek, S.; Kreppel, F. Fully detargeted polyethylene glycol-coated adenovirus vectors are potent genetic vaccines and escape from pre-existing anti-adenovirus antibodies. Mol. Ther. 2008, 16, 154-162.
134. Hofherr, S. E.; Shashkova, E. V.; Weaver, E. A.; Khare, R.; Barry, M. A. Modification of adenoviral vectors with polyethylene glycol modulates in vivo tissue tropism and gene expression. Mol. Ther. 2008, 16, 1276-1282.
135. Weaver, E. A.; Barry, M. A. Effects of shielding adenoviral vectors with polyethylene glycol on vector-specific and vaccine-mediated immune responses. Hum. Gene Ther. 2008, 19, 1369-1382.
136. Suzuki-Kouyama, E.; Katayama, K.; Sakurai, F.; Yamaguchi, T.; Kurachi, S.; Kawabata, K.; Nakagawa, S.; Mizuguchi, H. Hexonspecific PEGylated adenovirus vectors utilizing avidin-biotin interaction. Biomaterials 2011, 32, 1724-1730.
137. Tsutsumi, Y.; Tsunoda, S.; Kaneda, Y.; Kamada, H.; Kihira, T.; Nakagawa, S.; Yamamoto, Y.; Horisawa, Y.; Mayumi, T. In vivo anti-tumor efficacy of polyethylene glycol-modified tumor necrosis factor-alpha against tumor necrosis factor-resistant tumors. Jpn. J. Cancer Res. 1996, 87, 1078-1085.
138. Shibata, H.; Yoshioka, Y.; Ikemizu, S.; Kobayashi, K.; Yamamoto, Y.; Mukai, Y.; Okamoto, T.; Taniai, M.; Kawamura, M.; Abe, Y.; Nakagawa, S.; Hayakawa, T.; Nagata, S.; Yamagata, Y.; Mayumi, T.; Kamada, H.; Tsutsumi, Y. Functionalization of tumor necrosis factor-alpha using phage display technique and PEGylation improves its antitumor therapeutic window. Clin. Cancer Res. 2004, 10, 8293-8300.
139. Inada, Y.; Furukawa, M.; Sasaki, H.; Kodera, Y.; Hiroto, M.; Nishimura, H.; Matsushima, A. Biomedical and biotechnological applications of PEG- and PM-modified proteins. Trends Biotechnol. 1995, 13, 86-91.
140. Zhou, R.; Mazurchuk, R.; Straubinger, R. M. Antivasculature effects of doxorubicin-containing liposomes in an intracranial rat brain tumor model. Cancer Res. 2002, 62, 2561-2566.
141. Maeda, H.; Sawa, T.; Konno, T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control Release. 2001, 74, 47-61.
142. Maeda, H. SMANCS and polymer-conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 2001, 46, 169-185.
143. Matsumura, Y.; Maeda, H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986, 46, 6387-6392.
144. Greish, K.; Fang, J.; Inutsuka, T.; Nagamitsu, A.; Maeda, H. Macromolecular therapeutics: advantages and prospects with special emphasis on solid tumour targeting. Clin. Pharmacokinet. 2003, 42, 1089-1105.
145. Gabizon, A.; Catane, R.; Uziely, B.; Kaufman, B.; Safra, T.; Cohen, R.; Martin, F.; Huang, A.; Barenholz, Y. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res. 1994, 54, 987-92.
146. Croyle, M. A.; Chirmule, N.; Zhang, Y.; Wilson, J. M. PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver. Hum. Gene Ther. 2002, 13, 1887-1900.
147. Lanciotti, J.; Song, A.; Doukas, J.; Sosnowski, B.; Pierce, G.; Gregory, R.; Wadsworth, S.; O'Riordan, C. Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates. Mol. Ther. 2003, 8, 99-107.
148. Eto, Y.; Gao, J. Q.; Sekiguchi, F.; Kurachi, S.; Katayama, K.; Maeda, M.; Kawasaki, K.; Mizuguchi, H.; Hayakawa, T.; Tsutsumi, Y.; Mayumi, T.; Nakagawa, S. PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability. J. Gene Med. 2005, 7, 604-612.
149. Mok, H.; Palmer, D. J.; Ng, P.; Barry, M. A. Evaluation of polyethylene glycol modification of first-generation and helperdependent adenoviral vectors to reduce innate immune responses. Mol. Ther. 2005, 11, 66-79.
150. Ogawara, K.; Rots, M. G.; Kok, R. J.; Moorlag, H. E.; Van Loenen, A. M.; Meijer, D. K.; Haisma, H. J.; Molema, G. A novel strategy to modify adenovirus tropism and enhance transgene delivery to activated vascular endothelial cells in vitro and in vivo. Hum. Gene Ther. 2004, 15, 433-443.
151. Ogawara, K.; Kuldo, J. M.; Oosterhuis, K.; Kroesen, B. J.; Rots, M. G.; Trautwein, C.; Kimura, T.; Haisma, H. J.; Molema, G. Functional inhibition of NF-kappaB signal transduction in alphavbeta3 integrin expressing endothelial cells by using RGDPEG-modified adenovirus with a mutant IkappaB gene. Arthritis Res. Ther. 2006, 8, R32.
152. Kim, J.; Nam, H. Y.; Kim, T. I.; Kim, P. H.; Ryu, J.; Yun, C. O.; Kim, S. W. Active targeting of RGD-conjugated bioreducible polymer for delivery of oncolytic adenovirus expressing shRNA against IL-8 mRNA. Biomaterials. 2011, 32, 5158-5166.
153. Yao, X.; Yoshioka, Y.; Morishige, T.; Eto, Y.; Narimatsu, S.; Kawai, Y.; Mizuguchi, H.; Gao, J. Q.; Mukai, Y.; Okada, N.; Nakagawa, S. Tumor Vascular Targeted Delivery of Polymerconjugated Adenovirus Vector for Cancer Gene Therapy. Mol. Ther. 2011. doi: 10.1038/mt.2011.112.
154. Marshall, E. Gene therapy death prompts review of adenovirus vector. Science 1999, 286, 2244-2245.